MYGN

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Myriad Genetics Inc revenue for the last quarter amounts to 205.70M USD, decreased -3.56 % YoY.

Myriad Genetics Inc. EPS for the last quarter amounts to -0.29 USD, increased 20.83 % YoY.

Myriad Genetics Inc (MYGN) has 2700 emplpoyees as of December 15 2025.

Today MYGN has the market capitalization of 672.07M USD.